Clinical Trial Update: AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients [Phase 2]

View source ↗

Summary

A Phase 2 randomized trial assessing safety and tolerability of AZD3241 in Multiple System Atrophy (MSA) with PET imaging has completed; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple System Atrophy

Drugs mentioned

• AZD3241

Snippet

Sponsor: AstraZeneca | Conditions: Multiple System Atrophy, MSA | Phase 2 | Status: COMPLETED | Results posted: 2017-09-25